Circulating melatonin and the risk of breast and endometrial cancer in women

Cancer Letters

Volumn 281, Issue 1, 2009, Pages 1-7

  Viswanathan, Akila N ^a   Schernhammer, Eva S ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Melatonin; Treatment

Indexed keywords

AROMATASE; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; ENDOMETRIUM CANCER; HORMONE ACTION; HORMONE RELEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SHIFT WORKER; SHORT SURVEY; SLEEP;

EID: 67349240411     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.11.002     Document Type: Review

References (85)

1. Axelrod J., and Wurtman R.J. Photic and neural control of indolamine metabolism in the rat pineal gland. Adv. Pharmacol. 6(Pt A) (1968) 157-166
2. Kerenyi N.A., Pandula E., and Feuer G.M. Oncostatic effects of the pineal gland. Drug Metab. Drug Interact. 8 3-4 (1990) 313-319
3. Pandi-Perumal S.R., Trakht I., Srinivasan V., et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 85 3 (2008) 335-353
4. Srinivasan V., Spence D.W., Pandi-Perumal S.R., et al. Melatonin, environmental light, and breast cancer. Breast Cancer Res. Treat. 108 3 (2008) 339-350
5. Srinivasan V., Spence D.W., Pandi-Perumal S.R., Trakht I., and Cardinali D.P. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr. Cancer Ther. 7 3 (2008) 189-203
6. Stevens R.G. Electric power use and breast cancer: a hypothesis. Am. J. Epidemiol. 125 4 (1987) 556-561
7. Stevens R.G., Blask D.E., Brainard G.C., et al. Meeting report: the role of environmental lighting and circadian disruption in cancer and other diseases. Environ. Health Perspect. 115 9 (2007) 1357-1362
8. Schernhammer E.S., and Schulmeister K. Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels?. Br. J. Cancer 90 5 (2004) 941-943
9. American Cancer Society, Cancer Facts and Figures, American Cancer Society, Atlanta, GA, 2007.
10. Willett W.C., Rockhill B., Hankinson S.E., Hunter D., and Colditz G.A. Nongenetic Factors in the Causation of Breast Cancer. third ed. (2004), Lippincott, Williams and Wilkins, Philadelphia, PA
11. ACS, Cancer Facts and Figures, American Cancer Society, Atlanta, 2007.
12. Kaaks R., Lukanova A., and Kurzer M.S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol. Biomarkers Prev. 11 12 (2002) 1531-1543
13. Viswanathan A.N., Feskanich D., De Vivo I., et al. Smoking and the risk of endometrial cancer: results from the Nurses' Health Study. Int. J. Cancer 114 6 (2005) 996-1001
14. Blask D.E., Brainard G.C., Dauchy R.T., et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res. 65 23 (2005) 11174-11184
15. Blask D.E., Dauchy R.T., and Sauer L.A. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27 2 (2005) 179-188
16. Brzezinski A. Melatonin in humans. N. Engl. J. Med. 336 3 (1997) 186-195
17. Sainz R.M., Mayo J.C., Rodriguez C., Tan D.X., Lopez-Burillo S., and Reiter R.J. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell. Mol. Life Sci. 60 7 (2003) 1407-1426
18. Blask D.E., Sauer L.A., Dauchy R.T., Holowachuk E.W., Ruhoff M.S., and Kopff H.S. Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal. Cancer Res. 59 (1999) 4693-4701
19. Lissoni P., Rovelli F., Malugani F., Bucovec R., Conti A., and Maestroni G.J. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol. Lett. 22 1 (2001) 45-47
20. Vijayalaxmi, Thomas C.R.J., Reiter R.J., and Herman T.S. Melatonin: from basic research to cancer treatment clinics. J. Clin. Oncol. 20 10 (2002) 2575-2601
21. Kilic E., Kilic U., Reiter R.J., Bassetti C.L., and Hermann D.M. Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J. Pineal Res. 37 4 (2004) 247-251
22. Hill S.M., and Blask D.E. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res. 48 21 (1988) 6121-6126
23. Cos S., Gonzalez A., Guezmes A., et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int. J. Cancer 118 2 (2006) 274-278
24. Cos S., Blask D.E., Lemus-Wilson A., and Hill A.B. Effects of melatonin on the cell cycle kinetics and "estrogen-rescue" of MCF-7 human breast cancer cells in culture. J. Pineal Res. 10 1 (1991) 36-42
25. Cos S., Fernandez R., Guezmes A., and Sanchez-Barcelo E.J. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res. 58 (1998) 4383-4390
26. Ram P.T., Dai J., Yuan L., et al. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett. 179 2 (2002) 141-150
27. Yuan L., Collins A.R., Dai J., Dubocovich M.L., and Hill S.M. MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol. Cell. Endocrinol. 192 1-2 (2002) 147-156
28. del Rio B., Garcia Pedrero J.M., Martinez-Campa C., Zuazua P., Lazo P.R.S., and Ramos S. Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J. Biol. Chem. 279 37 (2004) 38294-38302
29. Lawson N.O., Wee B.E., Blask D.E., Castles C.G., Spriggs L.L., and Hill S.M. Melatonin decreases estrogen receptor expression in the medial preoptic area of inbred (LSH/SsLak) golden hamsters. Biol. Reprod. 47 6 (1992) 1082-1090
30. Molis T.M., Spriggs L.L., and Hill S.M. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol. Endocrinol. 8 12 (1994) 1681-1690
31. Rato A.G., Pedrero J.G., Martinez M.A., del Rio B., Lazo P.S., and Ramos S. Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J. 13 8 (1999) 857-868
32. Barrenetxe J., Delagrange P., and Martinez J.A. Physiological and metabolic functions of melatonin. J. Physiol. Biochem. 60 1 (2004) 61-72
33. Blask D.E., Sauer L.A., and Dauchy R.T. Melatonin as a chronobiotic/anticancer agent: cellular biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr. Trop. Med. Chem. 2 2 (2002) 113-132
34. Delagrange P., Atkinson J., Boutin J.A., et al. Therapeutic perspectives for melatonin agonists and antagonists. J. Neuroendocrinol. 15 4 (2003) 442-448
35. Karlsson B., Knutsson A., and Lindahl B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27,485 people. Occup. Environ. Med. 58 11 (2001) 747-752
36. Nachtigal M.C., Patterson R.E., Stratton K.L., Adams L.A., Shattuck A.L., and White E. Dietary supplements and weight control in a middle-age population. J. Altern. Complement Med. 11 5 (2005) 909-915
37. Alonso-Vale M.I., Borges-Silva C.N., Anhe G.F., et al. Light/dark cycle-dependent metabolic changes in adipose tissue of pinealectomized rats. Horm. Metab. Res. 36 7 (2004) 474-479
38. Reiter R.J., Tan D.X., Korkmaz A., et al. Light at night, chronodisruption, melatonin suppression, and cancer risk: a review. Crit. Rev. Oncog. 13 4 (2007) 303-328
39. Wu A.H., Wang R., Koh W.P., Stanczyk F.C., Lee H.P., and Yu M.C. Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis 29 6 (2008) 1244-1248
40. Nagata C., Nagao Y., Yamamoto S., Shibuya C., Kashiki Y., and Shimizu H. Light exposure at night, urinary 6-sulfatoxymelatonin, and serum estrogens and androgens in postmenopausal Japanese women. Cancer Epidemiol. Biomarkers Prev. 17 6 (2008) 1418-1423
41. Schernhammer E.S., Kroenke C.H., Dowsett M., Folkerd E., and Hankinson S.E. Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. J. Pineal Res. 40 2 (2006) 116-124
42. Hansen A., Grade A., and Hansen J. Diurnal urinary 6-sulfatxoymelatonin levels among healthy Danis nurses during work and leisure time. Chronobiol. Int. 23 6 (2006) 1203-1215
43. Yamauchi H., Iwamoto M., and Harada N. Physiological effects of shift work on hospital nurses. J. Hum. Ergol. (Tokyo) 30 1-2 (2001) 251-254
44. McElroy J.A., Newcomb P.A., Titus-Ernstoff L., Trentham-Dietz A., Hampton J.M., and Egan K.M. Duration of sleep and breast cancer risk in a large population-based case-control study. J. Sleep Res. 15 3 (2006) 241-249
45. Pinheiro S.P., Schernhammer E.S., Tworoger S.S., and Michels K.B. A prospective study on habitual duration of sleep and incidence of breast cancer in a large cohort of women. Cancer Res. 66 10 (2006) 5521-5525
46. Verkasalo P.K., Lillberg K., Stevens R.G., et al. Sleep duration and breast cancer: a prospective cohort study. Cancer Res. 65 20 (2005) 9595-9600
47. Kakizaki M., Kuriyama S., Sone T., et al. Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer 99 9 (2008) 1502-1505
48. Stevens R.G. Artificial lighting in the industrialized world: circadian disruption and breast cancer. Cancer Causes Control 17 4 (2006) 501-507
49. Garland F.C., Garland C.F., Gorham E.D., and Young J.F. Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev. Med. 19 6 (1990) 614-622
50. Hahn R.A. Profound bilateral blindness and the incidence of breast cancer. Epidemiology 2 3 (1991) 208-210
51. Feychting M., Oesterlund B., and Ahlbom A. Reduced cancer incidence among the blind. Epidemiology 9 5 (1998) 490-494
52. Pukkala E., Verkasalo P.K., Ojamo M., and Rudanko S.L. Visual impairment and cancer: a population-based cohort study in Finland. Cancer Causes Control 10 1 (1999) 13-20
53. Kliukiene J., Tynes T., and Andersen A. Risk of breast cancer among Norwegian women with visual impairment. Br. J. Cancer 84 3 (2001) 397-399
54. Lee D.J., Gomez-Marin O., Lam B.L., and Zheng D.D. Visual acuity impairment and mortality in US adults. Arch. Ophthalmol. 120 11 (2002) 1544-1550
55. Klein R., Klein B.E., Moss S.E., and Cruickshanks K.J. Association of ocular disease and mortality in a diabetic population. Arch. Ophthalmol. 117 11 (1999) 1487-1495
56. Schernhammer E.S., Laden F., Speizer F.E., et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J. Natl. Cancer Inst. 93 20 (2001) 1563-1568
57. E. Schernhammer, C. Kroenke, F. Laden, S. Hankinson, Night work and melatonin levels in women participating in the nurses' health study. II: Associate with breast cancer risk. In: Second Symposium of the Dana-Farber/Harvard Cancer Center Program in Breast Cancer, Boston, 2005.
58. Tynes T., Hannevik M., Andersen A., Vistnes A., and Haldorsen T. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control 7 2 (1996) 197-204
59. Hansen J. Breast cancer among women who work at night. Epidemiology 12 5 (2001) 588-589
60. Davis S., Mirick D.K., and Stevens R.G. Night shift work, light at night, and risk of breast cancer. J. Natl. Cancer Inst. 93 20 (2001) 1557-1562
61. Lie J.-A.S., Roessink J., and Kjaerheim K. Breast cancer and night work among Norwegian nurses. Cancer Causes & Control 17 1 (2006) 39-44
62. O'Leary E.S., Schoenfeld E.R., Stevens R.G., et al. Shift work, light at night, and breast cancer on Long Island, New York. Am. J. Epidemiol. 164 4 (2006) 358-366
63. Schwartzbaum J., Albohm A., and Feychting M. Cohort study of cancer risk among male and female shift workers. Scand J Work Environ Health 33 5 (2007) 336-343
64. Megdal S.P., Kroenke C.H., Laden F., Pukkala E., and Schernhammer E.S. Night work and breast cancer risk: a systematic review and meta-analysis. Eur. J. Cancer 41 13 (2005) 2023-2032
65. Reynolds P., Cone J., Layefsky M., Goldberg D.E., and Hurley S. Cancer incidence in California flight attendants (United States). Cancer Causes Control 13 4 (2002) 317-324
66. Bartsch C., Bartsch H., Jain A.K., Laumas K.R., and Wetterberg L. Urinary melatonin levels in human breast cancer patients. J. Neural Transm. 52 4 (1981) 281-294
67. Tamarkin L., Danforth D., Lichter A., et al. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science 216 4549 (1982) 1003-1005
68. Bartsch C., Bartsch H., Bellmann O., and Lippert T.H. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 67 6 (1991) 1681-1684
69. Bartsch C., Bartsch H., Fuchs U., Lippert T.H., Bellmann O., and Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer 64 2 (1989) 426-433
70. Bartsch C., Bartsch H., Karenovics A., Franz H., Peiker G., and Mecke D. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size. J. Pineal Res. 23 2 (1997) 53-58
71. Cook M.R., Graham C., Kavet R., Stevens R.G., Davis S., and Kheifets L. Morning urinary assessment of nocturnal melatonin secretion in older women. J. Pineal Res. 28 1 (2000) 41-47
72. Danforth D.N.J., Tamarkin L., Mulvihill J.J., Bagley C.S., and Lippman M.E. Plasma melatonin and the hormone-dependency of human breast cancer. J. Clin. Oncol. 3 7 (1985) 941-948
73. Falkson G., Falkson H.C., Steyn M.E., Rapoport B.L., and Meyer B.J. Plasma melatonin in patients with breast cancer. Oncology 47 5 (1990) 401-405
74. Graham C., Cook M.R., Kavet R., Sastre A., and Smith D.K. Prediction of nocturnal plasma melatonin from morning urinary measures. J. Pineal Res. 24 4 (1998) 230-238
75. Lissoni P., Bastone A., Sala R., et al. The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. Eur. J. Cancer Clin. Oncol. 23 7 (1987) 949-957
76. Lissoni P., Crispino S., Barni S., et al. Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology 47 3 (1990) 275-277
77. Skene D.J., Bojkowski C.J., Currie J.E., Wright J., Boulter P.S., and Arendt J. 6-Sulphatoxymelatonin production in breast cancer patients. J. Pineal Res. 8 3 (1990) 269-276
78. Bartsch C., Bartsch H., Fluchter S.H., Attanasio A., and Gupta D. Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones. J. Pineal Res. 2 2 (1985) 121-132
79. Schernhammer E.S., Berrino F., Krogh V., et al. Urinary 6-Sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 100 12 (2008) 898-905
80. E. S. Schernhammer, S. E. Hankinson, Urinary melatonin levels and breast cancer risk in the Nurses' Health Study cohort, Cancer Epidemiol. Biomarkers Prev., in press.
81. Travis R.C., Allen D.S., Fentiman I.S., and Key T.J. Melatonin and breast cancer: a prospective study. J. Natl. Cancer Inst. 96 6 (2004) 475-482
82. Schernhammer E.S., and Hankinson S.E. Urinary melatonin levels and breast cancer risk. J. Natl. Cancer Inst. 97 14 (2005) 1084-1087
83. Grin W G.W. A significant correlation between melatonin deficiency and endometrial cancer. Gynecol. Obstet. Invest. 45 (1998) 62-65
84. Kobayashi Y., Itoh M.T., Kondo H., et al. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J. Pineal Res. 35 2 (2003) 71-74
85. Viswanathan A., Hankinson S.E., and Schernhammer E.S. Night shift work and the risk of endometrial cancer. Cancer Res. 67 21 (2007) 10618-10622